WO2014042981A3 - Treating digital ulcers, hypertension, vasculitis conditions, or inflammatory myositis conditions - Google Patents

Treating digital ulcers, hypertension, vasculitis conditions, or inflammatory myositis conditions Download PDF

Info

Publication number
WO2014042981A3
WO2014042981A3 PCT/US2013/058435 US2013058435W WO2014042981A3 WO 2014042981 A3 WO2014042981 A3 WO 2014042981A3 US 2013058435 W US2013058435 W US 2013058435W WO 2014042981 A3 WO2014042981 A3 WO 2014042981A3
Authority
WO
WIPO (PCT)
Prior art keywords
conditions
vasculitis
hypertension
inflammatory myositis
digital ulcers
Prior art date
Application number
PCT/US2013/058435
Other languages
French (fr)
Other versions
WO2014042981A2 (en
Inventor
Samir Rashmikant PATEL
Original Assignee
Digital Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Digital Therapeutics Llc filed Critical Digital Therapeutics Llc
Publication of WO2014042981A2 publication Critical patent/WO2014042981A2/en
Publication of WO2014042981A3 publication Critical patent/WO2014042981A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

This document provides methods and materials for treating digital ulcers, pulmonary arterial hypertension, vasculitis conditions, inflammatory myositis conditions, or combinations thereof. For example, methods and materials involved in using an inhibitor of a CD40-CD40L interaction to treat digital ulcers, pulmonary arterial hypertension, vasculitis conditions, inflammatory myositis conditions, or combinations thereof are provided.
PCT/US2013/058435 2012-09-17 2013-09-06 Treating digital ulcers, hypertension, vasculitis conditions, or inflammatory myositis conditions WO2014042981A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201261702211P 2012-09-17 2012-09-17
US201261702199P 2012-09-17 2012-09-17
US201261702204P 2012-09-17 2012-09-17
US201261702206P 2012-09-17 2012-09-17
US61/702,206 2012-09-17
US61/702,211 2012-09-17
US61/702,199 2012-09-17
US61/702,204 2012-09-17

Publications (2)

Publication Number Publication Date
WO2014042981A2 WO2014042981A2 (en) 2014-03-20
WO2014042981A3 true WO2014042981A3 (en) 2015-05-07

Family

ID=50278837

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/058435 WO2014042981A2 (en) 2012-09-17 2013-09-06 Treating digital ulcers, hypertension, vasculitis conditions, or inflammatory myositis conditions

Country Status (1)

Country Link
WO (1) WO2014042981A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3574017A1 (en) 2017-01-27 2019-12-04 Kymab Limited Anti-opg antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2312315A1 (en) * 2005-05-18 2011-04-20 Novartis AG Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
WO2011159693A2 (en) * 2010-06-15 2011-12-22 United Therapeutics Corporation Oral treatment of digital ischemic lesions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2312315A1 (en) * 2005-05-18 2011-04-20 Novartis AG Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
WO2011159693A2 (en) * 2010-06-15 2011-12-22 United Therapeutics Corporation Oral treatment of digital ischemic lesions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALLANORE Y ET AL.: "Increased plasma soluble CD 40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers", ANN RHEUM DIS, vol. 64, 2005, pages 481 - 483 *

Also Published As

Publication number Publication date
WO2014042981A2 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
NZ739252A (en) Monoclonal antibodies against bcma
WO2017015622A8 (en) Gdf11 binding proteins and uses thereof
EA201490886A1 (en) BIOMASS PROCESSING
WO2012051210A3 (en) Mesenchymal stem cells and related therapies
WO2013006490A3 (en) Antibodies that specifically bind to tim3
UA114611C2 (en) PESTICIDIC COMPOSITIONS AND METHODS RELATING TO THEM
GT201400147A (en) PYRIMIDINES AND FUSIONATED TRIAZINS REPLACED AND ITS USE
MX2019008122A (en) Heterocycle amines and uses thereof.
IN2015DN02636A (en)
EA201491215A1 (en) NON-TILED ANTI-INFLAMMATORY POLYPEPTIDES
BR112013032229A2 (en) hydrothermal hydrothermal biomass treatment method, and, composition
UY34676A (en) ? KNIFE FOR WOOD TREATMENT, METHODS FOR GALVANIZED AND TREATMENT OF KNIFE SURFACES FOR WOOD TREATMENT ?.
WO2012149439A3 (en) Il4/il13 binding repeat proteins and uses
HUP1100164A2 (en) Method and arrangement for the management of group shares especially in p2p enviroments
CO7020867A2 (en) Antibody formulations and methods
WO2016164896A3 (en) Modulation of smn expression
IT1400509B1 (en) EQUIPMENT AND METHOD FOR THE DEHYDRATION OF SLUDGE DEHYDRATION TREATMENT.
EP2729464B8 (en) Cyclopropyl-fused-1,3-thiazepines as bace 1 and/or bace 2 inhibitors
EA201490450A1 (en) NEW ENZYME INHIBITORS
MX337203B (en) Novel jnk inhibitor molecules.
AR095977A1 (en) A PROCEDURE TO INCREASE THE FORMATION OF PYROGLUTAMIC ACID OF A PROTEIN
DK2801611T3 (en) MICRO-ORGANISM THAT CAN PRODUCT L-AMINO ACID AND PROCEDURE FOR PREPARING L-AMINO ACID USING THE SAME
MX2014004074A (en) Methods of treating liver conditions using notch2 antagonists.
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
CL2012003491A1 (en) Compound derived from dihydropyrrole substituted; process to prepare these derivatives in stereoselective form.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13837068

Country of ref document: EP

Kind code of ref document: A2